An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO® (delayed-release Budesonide Capsules) Treatment in Adult Patients with Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO® 16 Mg Once Daily Treatment in Real-world Clinical Practice
Latest Information Update: 09 Dec 2024
Price :
$35 *
At a glance
- Drugs Budesonide (Primary)
- Indications IgA nephropathy
- Focus Therapeutic Use
- Acronyms NefXtend
- Sponsors Calliditas Therapeutics
- 09 Dec 2024 New trial record